Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia

• Published in: Blood 2002-11, Vol.100 (10), p.3757-3760
• Main Authors: Schmiegelow, Kjeld, Garred, Peter, Lausen, Birgitte, Andreassen, Bente, Petersen, Bodil Laub, Madsen, Hans Ole
• Format: Article
• Language: English
• Subjects: Adolescent; Alleles; Biological and medical sciences; Case-Control Studies; Child; Child, Preschool; Gene Frequency; Genetic Variation; Genotype; Hematologic and hematopoietic diseases; Humans; Incidence; Infant; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Mannose-Binding Lectins - blood; Mannose-Binding Lectins - deficiency; Mannose-Binding Lectins - genetics; Medical sciences; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2002-06-1627

Epidemiological data indicate that acute lymphoblastic leukemia (ALL) could be induced by interactions between the immune system and early childhood infections. Mannose-binding lectin (MBL) plays a critical role in the immune response in early childhood before specific immune protection develops. We investigated whether there may be an association between childhood ALL and low-producing MBLgenotypes. Serum MBL levels depend on normal (A)or defective (O) alleles, and on normal (Y) or reduced (X) promoter activities. For this study, 137 noninfants with ALL and 250 controls were classified into 3 MBL genotype groups according to their influence on the serum level of functional MBL: group I, YA/YA andYA/XA (higher levels); group II, XA/XA andYA/O (intermediate levels); and group III, MBLinsufficiency with XA/O or O/O(MBL-deficient) genotypes. Compared with controls, cases more often had low-level genotypes (I/II/III: 63 [46%]/44 [32%]/30 [22%] vs 145 [58%]/65 [26%]/40 [16%];P = .02) and MBL deficiency (8.8% vs 2.8%;P = .009). Thus, the ALL odds ratio forMBL-deficient versus nondeficient individuals was 3.3 (95% CI, 1.3-8.7), whereas the ALL odds ratio for group I versus group II/III genotypes was 0.62 (95% CI, 0.41-0.94). MBL group III patients were significantly younger at diagnosis than patients in group I/II (median, 3.9 vs 5.2 years; P = .04). The study shows that the presence of low-level MBL genotypes is associated with an increased risk of childhood ALL, particularly with early age at onset.